These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35265842)

  • 1. Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing
    Tumbarello M; Raffaelli F; Cascio A; Falcone M; Signorini L; Mussini C; De Rosa FG; Losito AR; De Pascale G; Pascale R; Giacobbe DR; Oliva A; Farese A; Morelli P; Tiseo G; Meschiari M; Del Giacomo P; Montagnani F; Fabbiani M; Vargas J; Spanu T; Bassetti M; Venditti M; Viale P
    JAC Antimicrob Resist; 2022 Mar; 4(1):dlac022. PubMed ID: 35265842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meropenem/vaborbactam activity
    Romanelli F; Stolfa S; Morea A; Ronga L; Prete RD; Chironna M; Santacroce L; Mosca A
    Future Microbiol; 2021 Nov; 16():1261-1266. PubMed ID: 34674551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations.
    Oliva A; Al Ismail D; Arcari G; Miele MC; Casali E; Sacco F; Volpicelli L; De Angelis M; Mascellino MT; Cancelli F; Raponi G; Carattoli A; Venditti M
    J Glob Antimicrob Resist; 2023 Jun; 33():321-327. PubMed ID: 37086891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in
    Rogers TM; Kline EG; Griffith MP; Jones CE; Rubio AM; Squires KM; Shields RK
    JAC Antimicrob Resist; 2023 Oct; 5(5):dlad113. PubMed ID: 37901589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study.
    Tumbarello M; Raffaelli F; Giannella M; De Pascale G; Cascio A; De Rosa FG; Cattelan AM; Oliva A; Saracino A; Bassetti M; Mussini C; Luzzati R; Capone A; Signorini L; Bartoletti M; Sambo M; Sarmati L; Antinori S; Mularoni A; Tascini C; Corona A; Pascale R; Rubino R; Corcione S; Mazzitelli M; Giuliano G; Lovecchio A; Bavaro DF; Meschiari M; Montagnani F; Fabbiani M; De Benedetto I; Antonelli M; Venditti M; Viale P
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae273. PubMed ID: 38854388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant
    Oliva A; Campogiani L; Savelloni G; Vitale P; Lodi A; Sacco F; Imeneo A; Volpicelli L; Polani R; Raponi G; Sarmati L; Venditti M
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad327. PubMed ID: 37476077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
    Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of KPC Variant and Porin Genotype on the
    Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target
    Hayden DA; White BP; Bennett KK
    J Pharm Technol; 2020 Oct; 36(5):202-210. PubMed ID: 34752560
    [No Abstract]   [Full Text] [Related]  

  • 10. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512
    Tiseo G; Falcone M; Leonildi A; Giordano C; Barnini S; Arcari G; Carattoli A; Menichetti F
    Open Forum Infect Dis; 2021 Jun; 8(6):ofab141. PubMed ID: 34189161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing
    Gaibani P; Lombardo D; Bussini L; Bovo F; Munari B; Giannella M; Bartoletti M; Viale P; Lazzarotto T; Ambretti S
    Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34066420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of
    Rogers TM; Kline EG; Griffith MP; Jones CE; Rubio AM; Squires KM; Shields RK
    JAC Antimicrob Resist; 2023 Apr; 5(2):dlad022. PubMed ID: 36968951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin.
    Volpicelli L; Cairoli S; Al Ismail D; Baisi F; Sacco F; Goffredo BM; Venditti M; Oliva A
    J Glob Antimicrob Resist; 2024 Jun; 37():86-90. PubMed ID: 38519025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant
    Belati A; Bavaro DF; Diella L; De Gennaro N; Di Gennaro F; Saracino A
    Antibiotics (Basel); 2022 Mar; 11(3):. PubMed ID: 35326836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood.
    Papalini C; Sabbatini S; Monari C; Mencacci A; Francisci D; Perito S; Pasticci MB
    J Glob Antimicrob Resist; 2020 Dec; 23():4-8. PubMed ID: 32810638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thoracic aorta graft infection by avibactam-resistant KPC-producing
    Belati A; Novara R; Bavaro DF; Procopio A; Fico C; Diella L; Romanelli F; Stolfa S; Mosca A; Di Gennaro F; Saracino A
    Infez Med; 2022; 30(2):277-284. PubMed ID: 35693053
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Huang Y; Wu T; Perez O; Rana AP; Chen L; Kreiswirth BN; Satlin MJ; Bulman ZP
    Front Microbiol; 2021; 12():618087. PubMed ID: 33763041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
    Wenzler E; Scoble PJ
    Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
    Tsivkovski R; Lomovskaya O
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
    Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.